糖尿病微循环障碍临床用药专家共识(2021年版)

2021-04-20 中国微循环学会糖尿病与微循环专业委员会 中国医学前沿杂志(电子版)

微循环障碍是糖尿病慢性并发症发生的重要病理生理基础之一,早期对其进行干预有助于防治糖尿病血管并发症。

中文标题:

糖尿病微循环障碍临床用药专家共识(2021年版)

发布日期:

2021-04-20

简要介绍:

微循环障碍是糖尿病慢性并发症发生的重要病理生理基础之一,早期对其进行干预有助于防治糖尿病血管并发症。为了进一步加深对糖尿病微循环障碍的认识,规范临床医生合理选择改善糖尿病微循环障碍的药物,中国微循环学会糖尿病与微循环专业委员会基于循证医学证据的进展,对《糖尿病微循环障碍临床用药专家共识》进行了更新。

相关资料下载:
[AttachmentFileName(sort=1, fileName=糖尿病微循环障碍临床用药专家共识_2021年版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9c1e11c00223635e, title=糖尿病微循环障碍临床用药专家共识(2021年版), enTitle=, guiderFrom=中国医学前沿杂志(电子版), authorId=0, author=, summary=微循环障碍是糖尿病慢性并发症发生的重要病理生理基础之一,早期对其进行干预有助于防治糖尿病血管并发症。, cover=https://img.medsci.cn/20211022/1634913974714_1608702.jpg, journalId=0, articlesId=null, associationId=2046, associationName=中国微循环学会糖尿病与微循环专业委员会, associationIntro=中国微循环学会糖尿病与微循环专业委员会, copyright=0, guiderPublishedTime=Tue Apr 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">微循环障碍是糖尿病慢性并发症发生的重要病理生理基础之一,早期对其进行干预有助于防治糖尿病血管并发症。为了进一步加深对糖尿病微循环障碍的认识,规范临床医生合理选择改善糖尿病微循环障碍的药物,中国微循环学会糖尿病与微循环专业委员会基于循证医学证据的进展,对《糖尿病微循环障碍临床用药专家共识》进行了更新。</span></p>, tagList=[TagDto(tagId=216, tagName=糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=216, guiderKeyword=糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=18666, appHits=222, showAppHits=0, pcHits=668, showPcHits=18443, likes=1, shares=30, comments=10, approvalStatus=1, publishedTime=Mon Oct 25 16:56:23 CST 2021, publishedTimeString=2021-04-20, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Mon Oct 25 16:28:05 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 21:09:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=糖尿病微循环障碍临床用药专家共识_2021年版.pdf)])
糖尿病微循环障碍临床用药专家共识_2021年版.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1203510, encodeId=625b120351066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162b5598790, createdName=ms3000000874455998, createdTime=Thu Mar 17 17:14:53 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080616, encodeId=738d10806160d, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:03 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074099, encodeId=15ee10e409997, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88c45709135, createdName=ms2000000007955373, createdTime=Fri Nov 26 09:52:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070503, encodeId=986210e050315, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bdab1671954, createdName=1de1330fm57(暂无匿称), createdTime=Mon Nov 15 19:50:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070048, encodeId=480110e0048b6, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98f05425253, createdName=ms5000000979632161, createdTime=Sun Nov 14 07:36:56 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2022-03-17 ms3000000874455998

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1203510, encodeId=625b120351066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162b5598790, createdName=ms3000000874455998, createdTime=Thu Mar 17 17:14:53 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080616, encodeId=738d10806160d, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:03 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074099, encodeId=15ee10e409997, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88c45709135, createdName=ms2000000007955373, createdTime=Fri Nov 26 09:52:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070503, encodeId=986210e050315, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bdab1671954, createdName=1de1330fm57(暂无匿称), createdTime=Mon Nov 15 19:50:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070048, encodeId=480110e0048b6, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98f05425253, createdName=ms5000000979632161, createdTime=Sun Nov 14 07:36:56 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1203510, encodeId=625b120351066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162b5598790, createdName=ms3000000874455998, createdTime=Thu Mar 17 17:14:53 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080616, encodeId=738d10806160d, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:03 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074099, encodeId=15ee10e409997, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88c45709135, createdName=ms2000000007955373, createdTime=Fri Nov 26 09:52:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070503, encodeId=986210e050315, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bdab1671954, createdName=1de1330fm57(暂无匿称), createdTime=Mon Nov 15 19:50:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070048, encodeId=480110e0048b6, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98f05425253, createdName=ms5000000979632161, createdTime=Sun Nov 14 07:36:56 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-26 ms2000000007955373

    有收获

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1203510, encodeId=625b120351066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162b5598790, createdName=ms3000000874455998, createdTime=Thu Mar 17 17:14:53 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080616, encodeId=738d10806160d, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:03 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074099, encodeId=15ee10e409997, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88c45709135, createdName=ms2000000007955373, createdTime=Fri Nov 26 09:52:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070503, encodeId=986210e050315, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bdab1671954, createdName=1de1330fm57(暂无匿称), createdTime=Mon Nov 15 19:50:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070048, encodeId=480110e0048b6, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98f05425253, createdName=ms5000000979632161, createdTime=Sun Nov 14 07:36:56 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1203510, encodeId=625b120351066, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162b5598790, createdName=ms3000000874455998, createdTime=Thu Mar 17 17:14:53 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080616, encodeId=738d10806160d, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:03 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074099, encodeId=15ee10e409997, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88c45709135, createdName=ms2000000007955373, createdTime=Fri Nov 26 09:52:12 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070503, encodeId=986210e050315, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bdab1671954, createdName=1de1330fm57(暂无匿称), createdTime=Mon Nov 15 19:50:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070048, encodeId=480110e0048b6, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98f05425253, createdName=ms5000000979632161, createdTime=Sun Nov 14 07:36:56 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 ms5000000979632161

    学到了

    0

拓展阅读

2009 中国糖尿病护理及教育指南

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2009-10-30

2010CARI 2型糖尿病患者的肾功能评估

澳大利亚肾病指南委员会(CARI,Caring for Australasians with Renal Impairment) · 2010-01-01

2010CARI 2型糖尿病患者中慢性肾脏病的预防和管理

澳大利亚肾病指南委员会(CARI,Caring for Australasians with Renal Impairment) · 2010-01-01

2010 AOA(POA)糖尿病患者眼部健康

美国视觉协会(AOA,American Optometric Association) · 2010-01-01

中国糖尿病医学营养治疗指南 (2010年)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2010-01-01

运动与2型糖尿病联合声明

美国糖尿病学会(ADA,American Diabetes Association) · 2010-01-01